Trial Profile
Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Anal cancer; Biliary cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Endometrial cancer; Glioblastoma; Malignant-mesothelioma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
- Focus Biomarker; Proof of concept; Registrational; Therapeutic Use
- Acronyms KEYNOTE-028
- Sponsors Merck Sharp & Dohme
- 12 May 2021 Status changed from active, no longer recruiting to completed.
- 25 Mar 2021 Planned End Date changed from 18 Dec 2023 to 30 Apr 2021.
- 25 Mar 2021 Planned primary completion date changed from 18 Dec 2023 to 30 Apr 2021.